bivamelagon
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 10, 2025 (NCT07156578)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanocortin receptor 4AGONIST
MC4R agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C(=O)N([C@H]1C[C@@H](C(=O)N2CCOCC2)N(C(=O)[C@@H]2CCN(C(C)(C)C)[C@H]2c2ccc(Cl)cc2)C1)[C@H]1CC[C@@H](C)CC1- Mol. weight
- 629.29 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314508 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07156578 | Phase 2 | Nov 10, 2025 | Rhythm Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1